Olema Oncology, Inc.

OLMA Nasdaq SEC CIK 1750284
Follow Olema Oncology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$73.6M −74.3% vs same quarter last year
EPS, diluted −$0.73 −49% vs same quarter last year
Operating cash flow −$47.1M −36.4% vs same quarter last year
Operating income −$77.5M −69% vs same quarter last year
Net income by quarter
−$33.6M
−$30.4M
−$43.8M
−$42.2M
−$46.1M
−$53.1M
−$63.2M
−$73.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$200M−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$162.5M
FY24−$129.5M
FY23−$96.7M
FY22−$104.8M
FY21−$71.1M
FY20−$22.1M
FY19−$4.3M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$104.5M
FY23-
FY22−$82.4M
FY21−$52.3M
FY20−$19.9M
FY19-
FY18-